Related Experiment Video

Updated: Jul 17, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)

Alison Reid1, Laura Vidal, Heather Shaw

  • 1Royal Marsden Hospital, The Institute of Cancer Research, Centre for Cancer Therapeutics, Downs Road, Sutton, Surrey SM2 5PT, UK.

European Journal of Cancer (Oxford, England : 1990)
|January 9, 2007
PubMed

Insights

Dual inhibition of epidermal growth factor receptor (EGFR) and HER2 offers a promising anti-cancer strategy. New therapies targeting both EGFR and HER2 are advancing, showing clinical benefits in refractory cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeting epidermal growth factor receptor (EGFR) and HER2 is an established anti-cancer approach.
  • The ErbB network exhibits heterodimerization, crosstalk, and redundancy, necessitating dual inhibition strategies.
  • Existing therapies like trastuzumab and cetuximab are being investigated in combination for cancer treatment.

Purpose of the Study:

  • To review the scientific rationale and emerging therapeutic strategies for dual inhibition of EGFR and HER2.
  • To highlight new generations of small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mABs) targeting the ErbB network.
  • To discuss the clinical potential of agents like lapatinib, BIBW-2992, HKI-272, and pertuzumab.

Main Methods:

  • Review of scientific literature and clinical trial data on ErbB-targeted therapies.
  • Analysis of the mechanisms of action for small molecule TKIs and monoclonal antibodies.
  • Evaluation of clinical benefits and FDA approval status of novel anti-cancer agents.

Main Results:

  • Lapatinib, a dual EGFR/HER2 TKI, demonstrates clinical benefit in trastuzumab-refractory breast cancer and is nearing FDA approval.
  • New irreversible TKIs (BIBW-2992, HKI-272) and a heterodimerization inhibitor (pertuzumab) targeting EGFR and HER2 are under investigation.
  • Combination therapies using approved agents are actively being explored in clinical trials.

Conclusions:

  • Dual inhibition of EGFR and HER2 is a scientifically sound strategy to overcome resistance mechanisms in the ErbB network.
  • A new wave of targeted therapies, including TKIs and mABs, offers improved treatment options for various cancers.
  • Ongoing clinical trials are crucial for validating the efficacy and safety of these novel dual-targeting agents.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...